HTG Molecular Diagnostics (HTGM) Stock Price, News & Analysis

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for HTG Molecular Diagnostics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" HTGM shares.
View HTGM analyst ratings or view top-rated stocks.

1 analysts have issued twelve-month price objectives for HTG Molecular Diagnostics' shares. Their HTGM share price targets range from $6.00 to $6.00. On average, they expect the company's stock price to reach $6.00 in the next twelve months.
View analysts price targets for HTGM or view top-rated stocks among Wall Street analysts.

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) released its earnings results on Wednesday, November, 10th. The medical research company reported ($0.60) EPS for the quarter, hitting the consensus estimate of ($0.60). The medical research company earned $2.52 million during the quarter, compared to the consensus estimate of $2.90 million. HTG Molecular Diagnostics had a negative net margin of 324.25% and a positive trailing twelve-month return on equity of 45.52%. During the same quarter in the prior year, the business posted ($1.05) earnings per share.

11 employees have rated HTG Molecular Diagnostics Chief Executive Officer Tim (TJ) Johnson on Glassdoor.com. Tim (TJ) Johnson has an approval rating of 47% among the company's employees. This puts Tim (TJ) Johnson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other HTG Molecular Diagnostics investors own include Idera Pharmaceuticals (IDRA), Biocept (BIOC), Rigel Pharmaceuticals (RIGL), Heat Biologics (HTBX), MEI Pharma (MEIP), Zosano Pharma (ZSAN), Verastem (VSTM), Aurinia Pharmaceuticals (AUPH), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

HTG Molecular Diagnostics (HTGM) raised $50 million in an IPO on Wednesday, May 6th 2015. The company issued 3,600,000 shares at $13.00-$15.00 per share. Leerink Partners served as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.